HSAs are characterized by an early, high metastatic rate. 4, 5 In patients diagnosed with splenic stage II HSA, chemotherapy (doxorubicin, or doxorubicin with an alkylating drug, or metronomic doses of cyclophosphamide and NSAIDs) following surgery will increase survival times by only a few months, with a median survival time of 5 to 6 months. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] Chemotherapy with doxorubicin or doxorubicin combined with DTIC, has shown variable efficacy in dogs with metastatic disease. 15, 16 Angiosarcoma is a rare human malignancy sharing a similar endothelial origin as seen in canine HSA. As in the canine disease, angiosarcoma displays an aggressive clinical behaviour and patients' outcomes are poor, with an overall 5-year survival of about 35% following multimodal therapy. 17 In people, angiosarcomas seem particularly responsive to taxanes, especially paclitaxel. 18, 19 Paclitaxel, a taxane chemotherapy drug, poisons the mitotic spindle, blocking the metaphase-anaphase transition during the cell cycle. 20 Prolonged arrest inhibits cell proliferation and results in apoptosis. [21] [22] [23] In addition to its direct cell-killing effect, paclitaxel has been shown to have anti-angiogenic characteristics. [24] [25] [26] This drug is commonly used in human cancers because of its broad spectrum of activity, including against Kaposi sarcomas and angiosarcomas. 19, 21, 23, 27 Paclitaxel has efficacy against various canine neoplasms, including mast cell tumours, osteosarcoma, mammary, pulmonary, anal sac carcinoma, HSA and histiocytic tumours, with response rates ranging from 20% to 86%. [28] [29] [30] [31] Paclitaxel (formulation with Cremophor EL and ethanol) is not commonly used in this species, because of high rates of hypersensitivity reactions (64%) when given intravenously. 22, 28, 32 A new Cremophor free, water-soluble, micellar formulation of paclitaxel (Paccal Vet; Oasmia Pharmaceuticals, Uppsala, Sweden) has been investigated and is well tolerated in dogs. [29] [30] [31] Dysregulation of tyrosine kinase pathways governing prolifera- may play a role in the growth and progression of human angiosarcoma. 39 Yonemaru et al 40 were able to detect the presence of bFGF and its receptor in canine HSA cell lines, suggesting an autocrine/ paracrine loop.
This study was performed to better understand the in vitro effects of micellar paclitaxel (Paccal Vet) against two canine HSA cells. 
| Drug
Paccal Vet was purchased from Oasmia (Uppsala, Sweden). The drug was reconstituted in sterile water to make a working stock solution with a final concentration of 1 mg/mL and was aliquoted into multiple tubes to avoid freeze-thaw cycles. The aliquots were immediately frozen at −80 C. Working concentrations were made fresh as needed prior to each experiment. Paclitaxel (micellar) was added to each plate in concentrations ranging from 0 (control) to 50 μg/mL (Cnt, 1 ng/mL, 5 ng/mL, 100 ng/mL, 500 ng/mL, 1 μg/mL, 5 μg/mL, 10 μg/mL, 50 μg/mL). 
| MTT assay

| Cell cycle analysis
Cell cycle analysis was performed to evaluate the effect of paclitaxel 
| Migration assay
To evaluate the migratory properties of DEN-HSA and Frog, a migra- CS4; Adobe System Inc., San Jose, California) was used to analyse the efficacy of closure and inhibition of circle space by the cell migration.
| Statistics
Graph Pad Prism (Graph Pad Prism, La Jolla, California) was used to calculate IC 50 and to generate graphs. Nonlinear regression to fit the data to the log (inhibitor) vs response (variable slope) curve were used in order to determine IC 50 . To summarize the data, the mean and SD were calculated for MTT assay, cell cycle assay, caspase Glo assay, Annexin V assay, migration assay, qPCR assay and ELISA. Two tailed unpaired t test was used to compare untreated and treated groups in cell cycle assay, caspase Glo assay and Annexin V assay. To investigate the association between longitudinal measurement of cancer cell closure rate and the treatment group in migration assay, we fit linear mixed models with subject specific random effects using R package lme4, which account for the within subject correlation. 47 To compare gene expression in each time point, analysis of variance (ANOVA) was used, and then Tukey post hoc test was conducted. A P value <0.05 was considered significant. Table S1 , Supporting Information). In all control samples, peaks were observed in G1 phase.
| Effects of paclitaxel (micellar) on apoptosis 3.3.1 | Caspase Glo 3/7 assay
The IC 50 of paclitaxel (micellar) caused a significant increase in caspase 3/7 activity at 24, 48 and 72 hours for DEN-HSA and Frog except at 72 hours in Frog (P < 0.05). A significant decrease in caspase 3/7 activity was observed at 72 hours for Frog (P < 0.05) ( Figure 3 , Table S2 ). All data were normalized to control (untreated).
| Annexin-V assay
Flow cytometric analysis (Annexin-V and PI stain) showed a significant increase in early and late apoptosis for both treated HSA cell lines for the majority of the time points ( Figure 4 and Table S3 ).
| Paclitaxel (micellar) affects the migratory ability of HSA cell lines
Migration closure endpoints were variable between the two HSA cell lines. The closure endpoints in DEN-HSA and Frog were 54 and 36 hours, respectively. Significant inhibition of migration was seen at various time points after exposure to the IC 50 of paclitaxel (micellar) (P < 0.05) ( Figure 5A ,B and Table S4 ). Table S6 ).
| DISCUSSION
This study demonstrated that increasing concentration of paclitaxel (micellar) caused a decrease in cell viability in both HSA cell lines. IC 50
for each cell line at 24, 48 and 72 hours ranged from 7 to 610 ng/mL, which is lower than the clinically achievable peak plasma concentration, 14 μg/mL. The findings reported in this study suggest that paclitaxel (micellar) can cause significant cytotoxicity to canine DEN-HSA and Frog cells at levels expected to be achievable in vivo, and therefore this drug could, in theory, be effective for the treatment of canine HSA in vivo.
| CONCLUSION
To the author's knowledge, this is the first study reporting the in vitro effects of a taxane drug on canine HSA. The anti-HSA effect of paclitaxel (micellar) seen in our study can, in large part, be attributed to the apoptosis initiating activity of the drug. In this study, the IC 50 of pacli- 
